Gri Bio Etf Profile
| GRI Etf | USD 2.00 0.01 0.50% |
PerformanceInsignificant
| Odds Of DistressLow
|
GRI Bio is trading at 2.00 as of the 22nd of July 2025. This is a 0.50% up since the beginning of the trading day. The etf's open price was 1.99. GRI Bio has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat insignificant performance during the last 90 days. The performance scores are derived for the period starting the 23rd of April 2025 and ending today, the 22nd of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of February 2021 | Category Healthcare | Classification Health Care |
The investment seeks investment results that correspond generally to the performance, before the funds fees and expenses, of an index called the Cohen Steers Global Realty Majors Index. Cohen Steers is traded on Archipelago Exchange in USA. The company has 2.5 M outstanding shares of which 58.2 K shares are currently shorted by investors with about 0.18 days to cover. More on GRI Bio
Moving against GRI Etf
GRI Etf Highlights
| President Director | Marc Hertz |
| Old Name | Gino Rossi S.A. |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Average Analyst Recommendation Analysts covering GRI Bio report their recommendations after researching GRI Bio's financial statements, talking to executives and customers, or listening in on GRI Bio's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering GRI Bio. The GRI consensus assessment is calculated by taking the average forecast from all of the analysts covering GRI Bio. | |
| Total Current Liabilities | 1.64 Million |
| Total Stockholder Equity | 4.03 Million |
| Currency Code | USD |
| Fiscal Year End | December |
| Stock Based Compensation | 148,000 |
| Property Plant And Equipment Net | 124,000 |
| Begin Period Cash Flow | 1.81 Million |
| Net Debt | (4.91 Million) |
| Accounts Payable | 897,000 |
| Cash | 5.03 Million |
| Other Operating Expenses | 8.23 Million |
| Non Current Assets Total | 124,000 |
| Cash And Short Term Investments | 5.03 Million |
| 50 Day M A | 1.4598 |
| Code | GRI |
| Common Stock Shares Outstanding | 183,276 |
GRI Bio [GRI] is traded in USA and was established 2008-05-07. GRI Bio is listed under Biotechnology category by Fama And French industry classification. The fund is classified under Health Care category within Biotechnology family. GRI Bio currently have 5.74 M in assets under management (AUM). , while the total return for the last 3 years was 8.99%.
GRI Bio has about 183.82 M in cash with (8.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.3.
Check GRI Bio Probability Of Bankruptcy
Top GRI Bio Etf Constituents
| PLD | Prologis | Stock | Real Estate | |
| EQIX | Equinix | Stock | Real Estate | |
| SBAC | SBA Communications Corp | Stock | Real Estate | |
| AMT | American Tower Corp | Stock | Real Estate | |
| SPG | Simon Property Group | Stock | Real Estate | |
| MITEF | Mitsubishi Estate Co | Pink Sheet | Real Estate—Diversified | |
| VTR | Ventas Inc | Stock | Real Estate | |
| AVB | AvalonBay Communities | Stock | Real Estate |
GRI Bio Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in GRI Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
| Risk Adjusted Performance | 0.0884 | |||
| Jensen Alpha | 0.3198 | |||
| Total Risk Alpha | (0.41) | |||
| Sortino Ratio | 0.0801 |
GRI Bio Against Markets
Other Information on Investing in GRI Etf
GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.